Widely used:Recently Viewed
Clear All
Today’s Range
52 Week Range
Liquidity
Market cap
$4,760 Mln
P/E Ratio
54.9
P/B Ratio
5.03
Industry P/E
--
Debt to Equity
0.01
ROE
0.1 %
ROCE
10.25 %
Div. Yield
0 %
Book Value
31.55
EPS
2.97
CFO
$-296.75 Mln
EBITDA
$-338.60 Mln
Net Profit
$-269.83 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Krystal Biotech (KRYS)
| 7.60 | -6.03 | 16.41 | -0.89 | 32.49 | 30.34 | -- |
|
BSE Sensex
| 0.39 | 6.40 | 1.96 | 7.69 | 10.43 | 20.75 | 10.61 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
Krystal Biotech (KRYS)
| 26.04 | 56.60 | 13.25 | 16.58 | 8.34 | 166.51 | 96.80 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 | 9.57 | 20.86 | -9.70 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 36.19 | 10,117.70 | 20.54 | 23.13 | |
| 296.28 | 8,962.72 | 23.48 | 58.42 | |
| 24.72 | 9,739.03 | -- | -28.77 | |
| 101.38 | 9,903.71 | 30.43 | 14.16 |
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK... (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1/2 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania. Address: 2100 Wharton Street, Pittsburgh, PA, United States, 15203 Read more
Founder, Chairman, President & CEO
Mr. Krish S. Krishnan M.B.A., M.S.
Founder, Chairman, President & CEO
Mr. Krish S. Krishnan M.B.A., M.S.
Headquarters
Pittsburgh, PA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Krystal Biotech Inc (KRYS) stood at $ 1,056 Mln as on 31-Dec-24
The share price of Krystal Biotech Inc (KRYS) is $168.57 (NASDAQ) as of 17-Apr-2025 16:00 EDT. Krystal Biotech Inc (KRYS) has given a return of 32.49% in the last 3 years.
Krystal Biotech Inc (KRYS) has a market capitalisation of $ 4,760 Mln as on 17-Apr-2025. As per Value Research classification, it is a Small Cap company.
The P/E ratio of Krystal Biotech Inc (KRYS) is 54.90 times as on 17-Apr-2025.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Krystal Biotech Inc (KRYS) and enter the required number of quantities and click on buy to purchase the shares of Krystal Biotech Inc (KRYS).
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1/2 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania. Address: 2100 Wharton Street, Pittsburgh, PA, United States, 15203
The CEO & director of Mr. Krish S. Krishnan M.B.A., M.S.. is Krystal Biotech Inc (KRYS), and CFO & Sr. VP is Mr. Krish S. Krishnan M.B.A., M.S..
There is no promoter pledging in Krystal Biotech Inc (KRYS).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,012
|
|
|
990
|
|
|
974
|
|
|
896
|
| Krystal Biotech Inc. (KRYS) | Ratios |
|---|---|
|
Return on equity(%)
|
10.34
|
|
Operating margin(%)
|
35.52
|
|
Net Margin(%)
|
30.69
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Krystal Biotech Inc (KRYS) was $0 Mln.
$3.87
(
